Introduction

Coleus forskohlii extract (standardized to contain 95% forskolin) is potentially useful in skin care formulations, particularly as a conditioning agent. Coleus forskohlii belongs to the Natural Order Labiatae (Lamiaceae), a family of mints and that grows wild in the warm sub-tropical temperate areas in India, Burma and Thailand. In India, it is cultivated for use as a condiment. In traditional Indian systems of medicine, the roots of Coleus forskohlii are used as a tonic. Other therapeutically relevant properties include anthelmintic action and efficacy in the management of skin infections and eruptions. The plant is also used traditionally in veterinary practice.

Coleus forskohlii is the only known natural source of the unique adenylate cyclase activating phytonutrient, forskolin. Adenylate cyclase is the enzyme involved in the production of Cyclic Adenosine Monophosphate (cAMP), a significant biochemical agent in metabolic processes. Cyclic AMP is a "second messenger" hormone signaling.

Protocols of studies on cosmeceutical products performed /sponsored by Sabinsa Corporation are based on alternatives to animal testing. Any references to animal tests appearing in product informational materials are related to information from published scientific literature compiled therein.
system. In many hormone sensitive systems the hormone itself does not enter the target cell but binds to a receptor and indirectly affects the production of another molecule within the cell which then diffuses intracellularly to the target enzymes or a receptor inside the cell to produce the response. This intracellular mediator is called the second messenger. cAMP and therefore forskolin have marked physiological effects through such "second messenger" actions on various biochemical processes in the body. A recently patented application includes the potentiation of lean body mass and benefits in the management of mood disorders⁴. Potential topical applications include its role as a skin-conditioning agent to support localized fat loss on topical application⁵.

**Phytochemistry**

Forskolin is 7β-acetoxy-8,13-epoxy-1α,6β,9α-trihydroxylabd-14-en11-one (a diterpenoid compound) which directly activates adenylate cyclase⁶.

\[ M_{C_{32}H_{48}O_{7}} = 404 \]

**Pharmacological effects**

Research carried out over the last few decades has revealed the multifaceted pharmacological effects of forskolin. Most of these effects have been linked to the role of forskolin as an activator of adenylate cyclase⁷. The spectrum of potential therapeutic activities is represented in Figure 1⁷:

Protocols of studies on cosmeceutical products performed /sponsored by Sabinsa Corporation are based on alternatives to animal testing. Any references to animal tests appearing in product informational materials are related to information from published scientific literature compiled therein.
SABINSA CORPORATION
*Pharmaceuticals
*Fine Chemicals
*Cosmeceuticals
*Phytochemicals
*Herbal Extracts
*Specialty Chemicals

Figure 1: Spectrum of potential therapeutic activities of forskolin

Adenylate cyclase is also involved in the regulation of lipolysis or enzymatic breakdown of fat in the adipocytes (fat cells). Hormone sensitive lipase mediates lipolysis and this enzyme is activated through phosphorylation by protein kinase A that in turn is activated by cAMP.

Cosmeceutical applications

Topical fat reduction in specific areas of the body is a common concern for women. Ronsard popularized the term “cellulite” to describe the dimpling and “orange peel” external appearance of the thighs, the cause of which was attributed to the aging process by later researchers. The structure of subcutaneous adipose tissue accounts for the development of the “orange peel” appearance. Groups of fat cells are attached to the
underside of the dermis by fibrous connective tissue. As fat cells enlarge, the fibers are stretched and pull down on the underlying skin. This causes the indentation or dimpling of the skin called cellulite.

It has been demonstrated that adipose tissue metabolism varies from one region of the body to another, for example, in severely obese women losing weight after the jejuno-ileal bypass surgery, fat was seen to be absorbed more slowly in the thigh region than the abdominal region\(^\text{10}\). These differences lead to the hypothesis that localized application of agents that trigger lipolysis or fat

---

**FORSKOLIN**

\[ \downarrow \]

- stimulates
- adenylate cyclase enzyme
  \[ \downarrow \]
  - increases
- Cyclic AMP levels
  \[ \downarrow \]
  - activates
- Protein kinase
  \[ \downarrow \]
  - phosphorylates
- Active form of hormone-sensitive lipase
  \[ \rightarrow \]
  - stimulates
- Release of fatty acids from body adipose tissues

*Figure 2: Mechanism of lipolytic action of forskolin*

---

Protocols of studies on cosmeceutical products performed/sponsored by Sabinsa Corporation are based on alternatives to animal testing. Any references to animal tests appearing in product informational materials are related to information from published scientific literature compiled therein.
breakdown could help in cases of fat accumulation at specific subcutaneous sites\textsuperscript{4}. Forskolin accelerates lipolysis through the activation of hormone-sensitive lipase\textsuperscript{11} as shown in Figure 2.

The adrenoreceptors play important roles in the regulation of lipolysis. Adrenoreceptors are neurons that are activated by adrenaline (epinephrine) or similar substances. The relative number of $\beta$-2 and $\alpha$-2 adrenoreceptors on the surface of the fat cells determine the balance of lipolysis in those cells. Hormones such as estrogen influence the number of $\alpha$-2 and $\beta$-2 adrenergic receptors in the fat cells. Through the effects of estrogen, women more $\alpha$-2 adrenergic receptors in fat cells in the hip and thigh region\textsuperscript{12}. The $\alpha$-2 adrenoreceptors and the adenosine receptors in fat cells stimulate specific proteins [GTP inhibitory binding proteins ($G_i$ proteins)] that inhibit adenylate cyclase thereby inhibiting lipolysis. A healthy balance of lipolysis is maintained through the simultaneous action of the $\beta$-2-receptors that activate specific proteins [GTP binding proteins ($G_s$ proteins)] which in turn activate adenylate cyclase (and thereby cAMP), stimulating lipolysis. Due to the increased number of $\alpha$-2 adrenergic receptors in the hip and thigh region in women, fat mobilization becomes more difficult from these areas\textsuperscript{5}. $\beta$-
adrenergic stimulation and α-2-adrenergic inhibition has been reported
to increase lipolysis from fat cells\textsuperscript{13}.

Forskolin bypasses the adrenoreceptors, increasing cAMP levels directly,
thereby stimulating lipolysis. The beneficial effects of forskolin,
therefore, do not depend upon the sensitivity of the adrenergic
receptors, which can often decreases with age and other physiological
factors. Forskolin has also been shown to counteract the decreased
response of fat cells to epinephrine, associated with aging.

**Clinical studies:**
A clinical study performed in 1987\textsuperscript{13} established that regional fat loss from
the thigh in obese women could be effected through adrenergic modulation.
In this study, twenty eight obese women were placed on a calorie-restricted
diet and subjected to one of five topical treatments to one thigh three to five
times per week for four weeks: (1) isoproterenol injections; (2) cream
containing forskolin, aminophylline, and yohimbine; (3) yohimbine cream;
(4) forskolin cream; or (5) aminophylline cream. The opposite thigh was
treated with a placebo (injection or cream), serving as the control. The
treated thighs lost significantly more girth after treatment (both by injection
and by cream). Additionally, no adverse reactions were observed that could
be attributed to either the cream or the injections. The authors of this study

*Protocols of studies on cosmeceutical products performed /sponsored by Sabinsa Corporation are
based on alternatives to animal testing. Any references to animal tests appearing in product
informational materials are related to information from published scientific literature compiled therein.*
concluded that local fat reduction from the thigh could be safely accomplished, using agents that affect the adrenergic mechanisms.

In a double-blind clinical trial\(^5\), five overweight women were treated with an ointment containing forskolin (1.2 \( \times \) \( 10^{-5} \) mol/L), yohimbine (2.5 \( \times \) \( 10^{-4} \) mol/L) and aminophylline (1.3 \( \times \) \( 10^{-2} \) mol/L) in an aquaphor base on one thigh or the base alone (placebo) on the other thigh, for four weeks, five days per week. The subjects’ thighs were wrapped with warm 600 to 900 mOsm/L magnesium sulfate solutions for 30 minutes prior to each application to maximize transcutaneous absorption. An occlusive plastic wrap was placed over the area to which the ointment was applied for the entire study period.

Measurements of girth two-thirds of the way between the knee and the greater trochanter were used to measure fat loss at the end of the study period. Treated thighs showed significant decrease in girth fat loss as compared to untreated thighs with no significant changes in total body weight (Figure 3).

Protocols of studies on cosmeceutical products performed /sponsored by Sabinsa Corporation are based on alternatives to animal testing. Any references to animal tests appearing in product informational materials are related to information from published scientific literature compiled therein.
Figure 3: Changes in thigh circumference and total body weight in five subjects after treatment with ointment containing forskolin, aminophylline and yohimbine or placebo.

The decrease was attributed to the combined actions of forskolin, aminophylline and yohimbine that effected localized fat loss by different mechanisms – forskolin through cAMP and β-2 adrenoreceptor activation; aminophylline through adenosine receptor antagonistic action and inhibition of phosphodiesterase and yohimbine through α-2 adrenoreceptor antagonistic action.
A subsequent trial studied the effects of the individual components of the ointment. Eighteen women were divided into three groups of six each, each group receiving one of the active compounds. The women were placed on a 800 kcal/day diet and encouraged to engage in a walking program. As before, the warm wraps with magnesium sulfate were applied, but the occlusive plastic wrap was not used. Six women had one thigh treated with an ointment containing $25 \times 10^{-5}$ mol/L forskolin in aquaphor base while the other thigh was treated with the base alone. Thigh girth measurements were taken as before. Four of the six women completed the study and showed significant decrease in treated thigh girth ($p < 0.05$) as compared to the untreated thigh (Figure 4).

![Figure 4: Changes in thigh circumference and total body weight in four subjects after treatment with forskolin ointment or placebo](image)

*Protocols of studies on cosmeceutical products performed /sponsored by Sabinsa Corporation are based on alternatives to animal testing. Any references to animal tests appearing in product informational materials are related to information from published scientific literature compiled therein.*
The authors of this study concluded that localized fat loss could be effected through topical application of substances like forskolin that stimulate lipolysis.

The subcutaneous fat cells are stimulated first, the dimpling on the skin of the thigh is lost as tension is relieved on the connective tissue that attached to the under surface of the dermis.

Based on these clinical studies reported in literature, Coleus forskohlii extract 95% is potentially useful in dislodging localized fat deposits immediately under the skin, when applied topically. The recommended levels of use as a skin conditioning agent: 0.1 to 0.5% of a topical formulation, such as an ointment, cream or lotion. To improve transdermal penetration of the extract, 0.01-0.1% Cosmoperine® (a standardized preparation derived from black pepper, a registered trademark of Sabinsa Corporation) may be added to the formulation.

References


Protocols of studies on cosmeceutical products performed /sponsored by Sabinsa Corporation are based on alternatives to animal testing. Any references to animal tests appearing in product informational materials are related to information from published scientific literature compiled therein.

Protocols of studies on cosmeceutical products performed /sponsored by Sabinusa Corporation are based on *alternatives to animal testing*. Any references to animal tests appearing in product informational materials are related to information from published scientific literature compiled therein.